Siren LLC’s MapLight Therapeutics MPLT Stock Holding History

Siren LLC’s Portfolio MPLT Stock Details MPLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.1M	Hold	450,000	–	–	0.33%	59
2026 Q1	$9.15M	Hold	450,000	–	–	0.25%	61
2025 Q4	$7.9M	Buy	+450,000	New	+$7.54M	0.24%	57

Other funds holding MPLT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Siren LLC's MPLT Position: Q2 2026 in Review

Siren LLC held its MapLight Therapeutics (MPLT) position steady in Q2 2026 at 450,000 shares worth $16.1M. The position accounts for 0.33% of the portfolio, ranked #59.

Siren LLC first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

Siren LLC held 450,000 shares of MapLight Therapeutics worth $16.1M as of Q2 2026.
Siren LLC left its MapLight Therapeutics share count unchanged in Q2 2026.
MapLight Therapeutics made up 0.33% of Siren LLC's portfolio in Q2 2026, its #59 holding.
Siren LLC first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.